Our Decision Support Software (DSS) is where we enter all the data from clinical studies, such as genome sequencing and liquid biopsies. The data vary depending on the characteristics of the tumor and the clinical data of each patient.
This predictive method allows optimizing treatment in terms of drug dosage and its association with other antitumor agents to ensure better results with personalized treatments.
DSS is part of an individualized theranostic approach for each patient in order to diagnose and design treatments that act at the level of the genetic and molecular alterations of the patients to achieve a better response. In this way, we can prescribe drugs adapted to the genetic characteristics, and obviously to those of the tumor.
This idea is centered on Oncological Precision Medicine, which constitutes an essential tool for the application of diagnostics and the adaptation of treatments to the individual characteristics of each patient, all based on the integration of the genomic and molecular characteristics of both tumors and patients. In other words, the opportunity is pursued to give a particular patient a combination of drugs appropriate to his or her biological profile. This is therefore a powerful tool that improves effectiveness, avoids unnecessary side effects and rationalizes healthcare costs.
Companion Diagnostic Test (CDT)
We are developing a Companion Diagnostic Test (CDT) for predictive treatment response performed on tissue and blood samples.